BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst (Nasdaq: BCRX) announced that its compensation committee granted inducement equity to four newly hired employees effective Dec 1, 2025. The grants consist of stock options to purchase an aggregate of 57,100 shares and restricted stock units covering 46,400 shares, totaling 103,500 shares.

The options have an exercise price of $7.13 per share, equal to the closing price on the grant date, a 10-year term, and the options and RSUs vest in four equal annual installments beginning on the one-year anniversary, subject to continued service. Grants were made under BioCryst’s Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares, and restricted stock units (RSUs) covering an aggregate of 46,400 shares, of BioCryst common stock. The options and RSUs were granted as of December 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $7.13 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

FAQ

What equity did BioCryst (BCRX) grant on Dec 1, 2025?

BioCryst granted stock options for an aggregate of 57,100 shares and RSUs covering 46,400 shares, effective Dec 1, 2025.

What is the exercise price and term for the BioCryst (BCRX) options?

Each option has an exercise price of $7.13 (equal to the grant-date close) and a 10-year term.

How do the options and RSUs vest for the BCRX inducement grants?

The options and RSUs vest in four equal annual installments starting on the one-year anniversary of the grant, subject to continued service.

Under what plan and Nasdaq rule were the BioCryst inducement grants made?

The awards were granted under BioCryst’s Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement grants from BioCryst on Dec 1, 2025?

The compensation committee granted inducement equity to four newly hired employees.